CONMED (NYSE:CNMD) Price Target Raised to $46.00

CONMED (NYSE:CNMD) had its price target boosted by stock analysts at Wells Fargo & Company from $39.00 to $46.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential downside of 4.69% from the stock’s current price.

A number of other equities research analysts also recently weighed in on CNMD. Bank of America reaffirmed an “underperform” rating and set a $40.00 price target on shares of CONMED in a research note on Monday, June 29th. BMO Capital Markets started coverage on CONMED in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 price target for the company. Wall Street Zen upgraded CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CONMED in a research report on Thursday, June 4th. Finally, JPMorgan Chase & Co. reduced their target price on shares of CONMED from $43.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Five equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, CONMED currently has a consensus rating of “Reduce” and a consensus price target of $40.20.

CONMED Stock Up 11.7%

Shares of NYSE CNMD traded up $5.06 during mid-day trading on Thursday, reaching $48.27. The company had a trading volume of 127,295 shares, compared to its average volume of 554,804. CONMED has a twelve month low of $31.44 and a twelve month high of $56.63. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. The stock has a market capitalization of $1.45 billion, a PE ratio of 27.44, a price-to-earnings-growth ratio of 3.27 and a beta of 0.93. The stock’s 50 day moving average is $36.89 and its 200-day moving average is $38.39.

CONMED (NYSE:CNMD) last released its quarterly earnings data on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.28. CONMED had a return on equity of 13.84% and a net margin of 4.00%.The firm had revenue of $343.49 million during the quarter, compared to analysts’ expectations of $337.60 million. During the same quarter last year, the firm earned $1.15 earnings per share. The business’s revenue for the quarter was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities analysts anticipate that CONMED will post 4.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CONMED

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of CONMED by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company’s stock worth $149,588,000 after buying an additional 73,533 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of CONMED by 6.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,392,920 shares of the company’s stock valued at $49,250,000 after acquiring an additional 80,116 shares during the last quarter. Wasatch Advisors LP acquired a new position in shares of CONMED during the 3rd quarter valued at about $47,026,000. Cooke & Bieler LP raised its stake in shares of CONMED by 23.2% in the 4th quarter. Cooke & Bieler LP now owns 867,817 shares of the company’s stock valued at $35,233,000 after acquiring an additional 163,494 shares in the last quarter. Finally, Deerfield Management Company L.P. raised its stake in shares of CONMED by 8.6% in the 3rd quarter. Deerfield Management Company L.P. now owns 760,196 shares of the company’s stock valued at $35,752,000 after acquiring an additional 59,925 shares in the last quarter.

Key Stories Impacting CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q2 earnings beat estimates. CONMED reported adjusted earnings of $1.38 per share, well above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million consensus forecast. CONMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year EPS guidance was raised or reaffirmed above Wall Street expectations. CONMED forecast fiscal 2026 earnings of $4.48 to $4.60 per share, compared with analyst expectations near $4.37. The guidance supports the bullish reaction because it indicates management expects earnings momentum to continue. Conmed Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying sales growth was stronger than the headline figure. Although reported sales increased only 0.3% year over year, revenue grew 6.0% organically when excluding the impact of previously announced strategic exits from certain gastrointestinal product offerings. This suggests the continuing business is performing better than reported growth implies. CONMED Corp Q2 2026 Earnings

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.